Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs
2022年3月14日 - 9:00PM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a
clinical-stage biopharmaceutical company, today announced the
appointment of Carolyn Finkle as senior vice president, head of
regulatory affairs. She becomes a member of the AMT executive
leadership team, reporting to chief executive officer and
co-founder of AMT, Tahir Mahmood, Ph.D.
“We are thrilled to welcome Carolyn as the
newest member of the executive leadership team at AMT,” said Dr.
Mahmood. “Carolyn’s extensive regulatory experience dovetails with
AMT’s focus to develop novel oral biologic products, targeting
multi-billion dollar markets, within the areas of mucosal
immunology. Her contributions will be instrumental for the company
as we anticipate further interactions with global regulatory
agencies following our four oral AMT-101 Phase 2 top-line data
readouts expected this year.”
Ms. Finkle joins with more than thirty years of
experience leading regulatory strategy, product development and
product approvals for global biotechnology organizations. Most
recently, Ms. Finkle served as chief operating officer and head of
regulatory affairs at Medicago. Prior to her role at Medicago, she
was the vice president of regulatory affairs at Karyopharm, head of
U.S. commercialization and global client partnerships at Kinapse,
and senior vice president of regulatory and pharmacovigilance at
inVentiv Health. Ms. Finkle also previously held leadership roles
in regulatory affairs and product development for Catalent,
MedImmune, PAREXEL and Celsion.
Ms. Finkle holds a BSc in Chemistry from the
University of Ottawa and an MSc from the University of Toronto. She
currently serves as an adjunct lecturer at Georgetown University
Graduate School and course co-director for the Pharmaceutical
Education and Research Institute (PERI).
“I am excited to be joining AMT, whose
breakthroughs in epithelial biology have led to the development of
a proprietary active transport technology platform and robust
multi-product pipeline,” said Ms. Finkle. “I look forward to
contributing to this next phase of growth as AMT works to bring
novel oral biologics to patients in need.”
About AMT-101AMT-101 is a novel
GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier
molecule, currently in development in four Phase 2 clinical trials
in inflammatory bowel diseases and rheumatoid arthritis. AMT-101 is
designed to cross the intestinal epithelial (IE) barrier with
limited entry into the bloodstream, thereby focusing IL-10 at the
primary site of inflammation in UC, along the intestinal tissue
lamina propria, potentially avoiding the side effects observed with
systemic administration.
About Applied Molecular Transport
Inc.AMT is a clinical-stage biopharmaceutical company
leveraging its proprietary technology platform to design and
develop a pipeline of novel oral biologic product candidates to
treat autoimmune, inflammatory, metabolic, and other diseases.
AMT’s proprietary technology platform allows it to exploit existing
natural cellular trafficking pathways to facilitate the active
transport of diverse therapeutic modalities across the IE barrier.
Active transport is an efficient mechanism that uses the cell’s own
machinery to transport materials across the IE barrier. AMT is
developing additional oral biologic product candidates in
patient-friendly oral forms that are designed to either target
local intestinal tissue or enter systemic circulation to precisely
address the relevant pathophysiology of disease.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com
Forward-Looking Statements
This press release contains forward-looking
statements as that term is defined in Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such forward-looking statements involve substantial risks and
uncertainties. All statements other than statements of historical
facts contained in this press release are forward-looking
statements including statements relating to AMT’s plans,
expectations, forecasts and future events. Such forward-looking
statements include, but are not limited to, the potential of, and
expectations regarding AMT’s technology platform and the extent to
which it may enable the development of new products and AMT’s
internal manufacturing capabilities, statements regarding scaling
our organization, statements regarding the potential size of the
markets for our product candidates, growth of clinical activities,
or pipeline expansion, statements regarding the optimization or
expansion of our product development plans or the design of future
clinical trials, statements regarding the potential of AMT-101,
AMT-126, AMT’s respiratory carrier technology or regarding AMT-101
and AMT-126 clinical trials, including the timing of data readouts
from such trials, advancing product candidates to future phases of
development, and program updates, milestones for such trials, and
our ability to replicate past clinical development strategies,
statements regarding the potential for AMT’s product candidates to
treat or provide clinically meaningful outcomes for certain medical
conditions or diseases, and assumptions regarding the biological
mode of action of our product candidates and the potential to avoid
side effects with our product candidates. In some cases, you can
identify forward-looking statements by terminology such as
“believe,” “estimate,” “intend,” “may,” “plan,” “potentially,”
“will,” “expect,” “enable,” “likely” or the negative of these terms
or other similar expressions. We have based these forward-looking
statements largely on our current expectations and projections
about future events and trends that we believe may affect our
financial condition, results of operations, business strategy and
financial needs. Actual events, trends or results could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements based on various factors.
Information regarding the foregoing and additional risks may be
found in the section entitled “Risk Factors” in AMT’s Annual and
Quarterly Reports on Form 10-K and 10-Q filed with the Securities
and Exchange Commission (the “SEC”), and AMT’s future reports to be
filed with the SEC. These forward-looking statements are made as of
the date of this press release, and AMT assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law.
Investor Relations
Contact:Andrew ChangHead, Investor Relations &
Corporate Communicationsachang@appliedmt.com
Media Contacts:Alexandra
SantosWheelhouse Life Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
過去 株価チャート
から 9 2024 まで 10 2024
Applied Molecular Transp... (NASDAQ:AMTI)
過去 株価チャート
から 10 2023 まで 10 2024